400 related articles for article (PubMed ID: 25447236)
1. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Masoud ST; Vecchio LM; Bergeron Y; Hossain MM; Nguyen LT; Bermejo MK; Kile B; Sotnikova TD; Siesser WB; Gainetdinov RR; Wightman RM; Caron MG; Richardson JR; Miller GW; Ramsey AJ; Cyr M; Salahpour A
Neurobiol Dis; 2015 Feb; 74():66-75. PubMed ID: 25447236
[TBL] [Abstract][Full Text] [Related]
2. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
3. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
[TBL] [Abstract][Full Text] [Related]
4. Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.
Lohr KM; Masoud ST; Salahpour A; Miller GW
Eur J Neurosci; 2017 Jan; 45(1):20-33. PubMed ID: 27520881
[TBL] [Abstract][Full Text] [Related]
5. Selective toxicity of L-DOPA to dopamine transporter-expressing neurons and locomotor behavior in zebrafish larvae.
Stednitz SJ; Freshner B; Shelton S; Shen T; Black D; Gahtan E
Neurotoxicol Teratol; 2015; 52(Pt A):51-6. PubMed ID: 26546233
[TBL] [Abstract][Full Text] [Related]
6. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
Choi HJ; Lee SY; Cho Y; Hwang O
Neurochem Int; 2005 Mar; 46(4):329-35. PubMed ID: 15707697
[TBL] [Abstract][Full Text] [Related]
8. Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
Stephenson DT; Childs MA; Li Q; Carvajal-Gonzalez S; Opsahl A; Tengowski M; Meglasson MD; Merchant K; Emborg ME
Cell Transplant; 2007; 16(3):229-44. PubMed ID: 17503735
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
[TBL] [Abstract][Full Text] [Related]
10. Acrylamide increases dopamine levels by affecting dopamine transport and metabolism related genes in the striatal dopaminergic system.
Pan X; Guo X; Xiong F; Cheng G; Lu Q; Yan H
Toxicol Lett; 2015 Jul; 236(1):60-8. PubMed ID: 25943760
[TBL] [Abstract][Full Text] [Related]
11. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
[TBL] [Abstract][Full Text] [Related]
12. Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons.
Hong J; Sha S; Zhou L; Wang C; Yin J; Chen L
Cell Death Dis; 2015 Jul; 6(7):e1832. PubMed ID: 26203861
[TBL] [Abstract][Full Text] [Related]
13. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
[TBL] [Abstract][Full Text] [Related]
14. Ginkgo biloba extract (EGb 761) modulates the expression of dopamine-related genes in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Rojas P; Ruiz-Sánchez E; Rojas C; Ogren SO
Neuroscience; 2012 Oct; 223():246-57. PubMed ID: 22885234
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
16. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice.
Chen L; Ding Y; Cagniard B; Van Laar AD; Mortimer A; Chi W; Hastings TG; Kang UJ; Zhuang X
J Neurosci; 2008 Jan; 28(2):425-33. PubMed ID: 18184785
[TBL] [Abstract][Full Text] [Related]
17. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
[TBL] [Abstract][Full Text] [Related]
18. Dopamine-dependent compensation maintains motor behavior in mice with developmental ablation of dopaminergic neurons.
Golden JP; Demaro JA; Knoten A; Hoshi M; Pehek E; Johnson EM; Gereau RW; Jain S
J Neurosci; 2013 Oct; 33(43):17095-107. PubMed ID: 24155314
[TBL] [Abstract][Full Text] [Related]
19. JNK inhibition of VMAT2 contributes to rotenone-induced oxidative stress and dopamine neuron death.
Choi WS; Kim HW; Xia Z
Toxicology; 2015 Feb; 328():75-81. PubMed ID: 25496994
[TBL] [Abstract][Full Text] [Related]
20. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Tillerson JL; Caudle WM; Reverón ME; Miller GW
Exp Neurol; 2002 Nov; 178(1):80-90. PubMed ID: 12460610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
